Gary Yeoman
Internal Medicine · Philadelphia, PANPI 1962430314
Payments from drug & device makers
Across 1,004 payments — averaging $2382.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$831K
- AbbVie$672K
- AstraZeneca$217K
- Boehringer Ingelheim$194K
- Hoffmann-la Roche Limited$163K
- Amgen$126K
- plus $190K from 27 others
Across 9 payments — averaging $3713.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$33K
What the payments were for
- Travel & lodging$2,25150%
- Food & beverage$2,28250%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 19 | $830,530 |
| AbbVie | 136 | $672,306 |
| AstraZeneca | 13 | $216,788 |
| Boehringer Ingelheim | 26 | $193,733 |
| Hoffmann-la Roche Limited | 15 | $163,091 |
| Amgen | 43 | $126,157 |
| Novo Nordisk AS | 538 | $100,462 |
| Alnylam Pharmaceuticals Inc. | 16 | $25,442 |
| Genentech, Inc. | 7 | $24,249 |
| Pfizer | 18 | $16,912 |
| Boehringer Ingelheim International GmbH | 99 | $13,710 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $1,279 |
| Novo Nordisk | 15 | $259 |
| Amarin Pharma, Inc. | 12 | $170 |
| Merck | 6 | $95 |
| Johnson & Johnson(2 entities) | 5 | $91 |
| Lilly USA, LLC | 5 | $72 |
| Astellas Pharma US Inc | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Nestle Healthcare Nutrition Inc. | 3 | $57 |
| Bayer | 3 | $50 |
| Vertos Medical, Inc. | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
| Abbott | 2 | $27 |
| Gilead | 2 | $26 |
| Orexo US, Inc. | 1 | $24 |
| Exact Sciences | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| GSK | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,392,470 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 11 | $207 |
| Atorvastatin Calcium | 14 | $127 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Walter KraftPhiladelphia$3.7M
- Daniel RaderPhiladelphia$3.3M
- Archna BajajPhiladelphia$2.9M
- Melina MarmarelisPhiladelphia$2.1M
- Adam WaxmanPhiladelphia$894K
- Donna GavaronePhiladelphia$728K
- Eyob FeyssaPhiladelphia$693K
- Meghan KaruturiPhiladelphia$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.